Dermata Therapeutics, Inc. (DRMA)
Nasdaq: DRMA · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2021
Income statement, as filed
In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Report filed | Mar 26, 2026 | Mar 17, 2025 | Mar 21, 2024 | Feb 21, 2023 | Mar 28, 2022 | · |
| For lenders | ||||||
| Net interest income | · | · | · | 63,573 | -45,613 | · |
| Research and development | 2,929,983 | 8,203,691 | 4,069,766 | 5,651,041 | 3,459,340 | 1,607,819 |
| Selling, general and administrative | 4,843,615 | 4,309,551 | · | · | · | · |
| General and administrative | · | 4,309,551 | 3,972,140 | 4,023,445 | 4,397,524 | 1,565,034 |
| Total operating expenses | 7,773,598 | 12,513,242 | 8,041,906 | 9,674,486 | · | · |
| Total costs and expenses | · | · | · | 9,674,486 | 7,856,864 | 3,172,853 |
| Operating income | -7,773,598 | -12,513,242 | -8,041,906 | -9,674,486 | -7,856,864 | -3,172,853 |
| Interest expense | · | · | · | · | 45,613 | 197,269 |
| Interest and investment income | 215,041 | 225,781 | 247,216 | 63,573 | · | · |
| Income tax expense | · | 0 | 0 | 0 | 0 | 0 |
| Net income including non-controlling interests | · | -12,287,461 | -7,794,690 | · | · | · |
| Net income | -7,558,557 | -12,287,461 | -7,794,690 | -9,610,913 | -7,902,477 | -3,236,530 |
| Preferred dividends | · | · | · | · | 2,293,199 | 0 |
| Net income to common shareholders | · | · | · | -9,610,913 | -10,464,714 | -3,236,530 |
| Earnings per share, basic | -8.16 | -80.32r | -39.99r | -13.92r | -2.43 | -1.69 |
| Earnings per share, diluted | -8.16 | -80.32r | -39.99 | · | · | · |
| Weighted average shares, basic | 926,192 | 152,974 | · | · | 4,302,232 | 1,911,009 |
| Weighted average shares, diluted | 926,192 | 152,974r | 194,928 | · | · | · |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Net interest income interest earned less interest paid
us-gaap:InterestIncomeExpenseNetResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseSelling, general and administrative the cost of selling and of running the company
us-gaap:SellingGeneralAndAdministrativeExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesTotal costs and expenses every operating cost, the cost of revenue included
us-gaap:OperatingCostsAndExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterest
us-gaap:InterestIncomeOtherIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossPreferred dividends paid to preferred holders before common shareholders
us-gaap:PreferredStockDividendsIncomeStatementImpactNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding